Navigation Links
CardioVascular BioTherapeutics, Inc. Announces Update on Timing of Form 10-K Filing
Date:4/21/2008

LAS VEGAS, April 21 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) has announced that the Over the Counter Bulletin Board (OTCBB), on which CVBT's stock is traded, has added a temporary "E" to the end of its ticker symbol. The temporary "E" designates the late filing of the Company's Annual Report (Form 10-K).

Pursuant to OTCBB rules, CVBT's listing will continue through May 15, 2008 provided the Company files it Annual Report before this date. After the OTCBB confirms the filing, the "E" will be removed from the ticker symbol.

On Friday, April 18th, CVBT submitted a Form 8-K stating that it was unable to file its Annual Report on time as additional time was necessary to ensure adequate disclosure of required information.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials underway in the areas of impaired wound healing seen in diabetes and in patients suffering from peripheral artery disease of the legs. An additional trial is also being conducted in patients with chronic back pain who may have perfusion defects to their spine.

CardioVascular BioTherapeutics, Inc.

Allison Lipson, (702) 839-7200

alipson@cvbt.com


'/>"/>
SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. BRISTOL-MYERS SQUIBB SELECTS ISIS DRUG TARGETING PCSK9 AS DEVELOPMENT CANDIDATE FOR PREVENTION AND TREATMENT OF CARDIOVASCULAR DISEASE
2. Significant Reductions in Mortality and Cardiovascular Events Shown Using Blood Pressure-Lowering Treatment in Those Aged 80 and Over
3. HealthAware Introduces Its VascularAware Cardiovascular Disease Module
4. GlaxoSmithKline Responds to JAMA Article on the ICES Thiazolidinediones and Cardiovascular Outcomes in Older Patients with Diabetes
5. VIA Pharmaceuticals Expands Clinical Advisory Board With Leading Experts in Cardiovascular Disease
6. VIA Pharmaceuticals Lead Compound, VIA-2291, Chosen as a Top Ten Most Licensable Cardiovascular Program for Windhover Informations Therapeutic Area Partnerships Conference
7. Amarin Announces Initiation of Cardiovascular Development Strategy
8. NFL Hall of Fame Legend Fred Biletnikoff Joins AFL/Signalife Cardiovascular Protection Team
9. Edwards Lifesciences Grants UC Irvine $5 Million to Establish the Edwards Lifesciences Center for Advanced Cardiovascular Technology
10. Legendary Earvin Magic Johnson Joins AFL/Signalife Cardiovascular Protection Team
11. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... 2017 , ... San Diego-based team building and cooking events company, Lajollacooks4u, has ... The bold new look is part of a transformation to increase awareness, appeal to ... period. , It will also expand its service offering from its signature gourmet cooking ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
(Date:10/9/2017)... DIEGO , Oct. 9, 2017  BioTech ... biological mechanism by which its ProCell stem cell ... critical limb ischemia.  The Company, demonstrated that treatment ... amount of limbs saved as compared to standard ... the molecule HGF resulted in reduction of therapeutic ...
Breaking Biology Technology:
(Date:3/28/2017)... , March 28, 2017 The ... Hardware (Camera, Monitors, Servers, Storage Devices), Software (Video Analytics, ... Region - Global Forecast to 2022", published by MarketsandMarkets, ... 2016 and is projected to reach USD 75.64 Billion ... and 2022. The base year considered for the study ...
(Date:3/24/2017)... 24, 2017 The Controller General of Immigration from ... Abdulla Algeen have received the prestigious international IAIR Award for the ... Continue Reading ... ... Controller Abdulla Algeen (small picture on the right) have received the IAIR ...
(Date:3/23/2017)... The report "Gesture Recognition and Touchless Sensing Market by Technology (Touch-based ... to 2022", published by MarketsandMarkets, the market is expected to be worth USD ... 2022. Continue Reading ... ... ...
Breaking Biology News(10 mins):